YSC-02

N/A

Report date: 2025/11/19 17:06:38

Base Information

Drug NameYSC-02

Drug Alias Nameoncolytic adenovirus therapy expressing shRNAs targeting TGF-beta + HSP2 (Yonsei University College of Medicine/Severance Biomedical Science Institute)YSC-02

ClassificationBiologics > Oncolytic virus

Mechanisms of ActionHeat shock protein beta-1 inhibitorsTransforming growth factor beta 2 inhibitors

TargetsTransforming growth factor beta 2Heat shock protein beta-1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesYonsei University

China Registration ClassN/A

Develop Information

Active CompaniesSeverance Biomedical Science Institute Yonsei University

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A